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Inmalaria parasites, mutations in two genes of folate biosynthesis encoding dihydrofolate reductase (dhfr)
and dihydropteroate synthase (dhps) modify responses to antifolate therapies which target these enzymes.
However, the involvement of other genes which modify the availability of exogenous folate, for example,
has been proposed. Here, we used short-read whole-genome re-sequencing to determine the mutations
in a clone of the rodent malaria parasite, Plasmodium chabaudi, which has altered susceptibility to both
sulphadoxine and pyrimethamine. This clone bears a previously identiﬁed S106N mutation in dhfr and
nomutation in dhps. Instead, three additional pointmutations in genes on chromosomes 2, 13 and 14were
identiﬁed. The mutated gene on chromosome 13 (mdr2 K392Q) encodes an ABC transporter. Because
Quantitative Trait Locus analysis previously indicated an association of genetic markers on chromosome
13 with responses to individual and combined antifolates, MDR2 is proposed to modulate antifolate
responses, possibly mediated by the transport of folate intermediates.
 2010 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
With the evolution of chloroquine resistance in malaria para-
sites in Africa and southeast Asia, the combination of the antifolate
drugs pyrimethamine (PYR) and sulphadoxine (SDX), commercially
known as Fansidar, was one of the mainstays of anti-malarial
drug therapy. Although resistance is now widespread, it is still
used in Africa, sometimes in combination with the artemisinin
derivative artesunate, to treat uncomplicated malaria (Nosten
and White, 2007). PYR and SDX synergistically inhibit enzyme
activities of the folate biosynthesis pathway, namely dihydrofolate
reductase (DHFR) and dihydropteroate synthetase (DHPS), both
encoded in bifunctional enzymes by dhfr-ts and pppk-dhps, respec-
tively (Supplementary Fig. S1). The folate pathway plays a critical
role in pyrimidine and DNA synthesis. The action of antifolate
drugs, the genetic basis of parasite resistance, and the complexities
of the relationships between parasite genotype and in vivo and
in vitro drug response phenotypes have been comprehensively
investigated (reviewed in Gregson and Plowe, 2005; Hyde, 2005;
Nzila, 2006).
Four point mutations in dhfr have been associated with the
development of PYR resistance in the human malaria parasitesitology Inc. Published by Elsevier
aper have been submitted to
elli).Plasmodium falciparum. The S108N point mutation is crucial for
the initial acquisition of PYR resistance: it interferes with the kinet-
ics of PYR binding to DHFR (Gregson and Plowe, 2005; Hyde, 2005;
Nzila, 2006). Subsequent mutations (N51I, C59R and I164L) are
thought to further increase resistance (Peterson et al., 1988; Basco
et al., 1995; Sirawaraporn et al., 1997; Nzila-Mounda et al., 1998).
Transfection studies show that the S108N mutation reduces the re-
sponse of malaria parasites to PYR (Wu et al., 1996). In populations
of P. falciparum ﬁeld isolates from Thailand, Laos and central Africa,
selective sweeps have been documented around dhfr on chromo-
some 4, where genetic hitchhiking has reduced genetic diversity
in PYR-resistant parasites relative to susceptible parasites (Nair
et al., 2003; Nash et al., 2005; McCollum et al., 2008).
SDX is an analogue of 4-aminobenzoic acid (pABA) – a substrate
of DHPS (Supplementary Fig. S1). SDX resistance has been linked
with several point mutations on the pppk-dhps gene: S436A,
A437G, K540E, A581G and A613S,T (Triglia and Cowman, 1994;
Plowe et al., 1997; Triglia et al., 1997; Wang et al., 1997). A number
of dhps allele combinations were tested in P. falciparum by trans-
fection, conﬁrming their role in SDX responses (Triglia et al.,
1998). However, a number of factors have impeded a clear formal
association between mutations in dhps and in vitro SDX and SDX/
PYR (S/P) responses. For example, the SDX response phenotype
may depend upon the availability of exogenous folate and pABA
(Milhous et al., 1985; Krungkrai et al., 1989; Wang et al., 1997,
1999), presumably because exogenous folate ‘bypasses’ the
requirement for DHPS activity (the ‘folate effect’; Wang et al.,Ltd. All rights reserved.
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that other genes effect SDX (or S/P) responses. For example, the
acquisition of PYR resistance by dhfr mutation may increase sus-
ceptibility to SDX (Hayton et al., 2002). Also, other genes may be
linked to the ‘folate effect’ (Wang et al., 1997); for example, it
has been proposed that mutations in the multi-drug resistance
protein 1 (MRP1) may contribute to S/P resistance (Dahlström
et al., 2009), possibly mediated by decreases in folate efﬂux from
the parasite. There have been other reports of SDX or S/P resistance
appearing without the apparent involvement of dhps mutation in
both human and rodent malaria (Hayton et al., 2002; Mberu
et al., 2000). This paper addresses the possible identities of such
genes.
The rodent malaria parasite Plasmodium chabaudi has been used
as an in vivo experimental model for the generation of drug-
resistant mutants by experimental evolution and the identiﬁcation
of the genes conferring the drug-resistance phenotypes (Carlton
et al., 2001). For example, the mutation conferring PYR resistance
in the experimentally selected AS-PYR clone (Fig. 1) is S106N dhfr
(Cowman and Lew, 1990; Cheng and Saul, 1994; Culleton et al.,
2005): this mutation is homologous to S108N in P. falciparum. As
also reported in P. falciparum (Eastham and Rieckmann, 1983),
the acquisition of PYR resistance in P. chabaudi is accompanied
by an increase in susceptibility to SDX (Jacobs, 1964; Hayton
et al., 2002). Subsequently, a single-step exposure of the AS-PYR
clone to a high dose of S/P selected a mutant clone (AS-50S/P)
which is more resistant to both S/P and SDX (Hayton et al., 2002)
than the AS-PYR progenitor (Fig. 1). These phenotypes are geneti-
cally stable. AS-50S/P has no mutation in the dhps gene, nor addi-
tional mutations in the dhfr gene (Hayton et al., 2002). In order to
map the genes underlying the modiﬁed drug response phenotypes,
Quantitative Trait Locus (QTL) analysis of 16 independent cloned
recombinant progeny of a genetic cross between the resistant par-
ent AS-50S/P and the genetically distinct susceptible parent AJ sug-
gested that loci on chromosomes 7 and 13 (chr07 and chr13) are
associated with PYR, SDX and S/P responses (Hayton et al., 2002).
As expected, for chr07 (containing dhfr), growth after PYR treat-
ment (and S/P) was associated with the inheritance of the mutant
AS allele: growth following SDX treatment was associated with
inheritance of wild-type AJ alleles. For chr13 markers, growth dur-Fig. 1. AS lineage of the Plasmodium chabaudi parasite clones used in the study. The
lineage progenitor clone AS-sens was selected for pyrimethamine (PYR) resistance,
giving rise to AS-PYR. Subsequently, AS-PYR was selected for sulphadoxine
(SDX)/PYR (S/P) resistance, resulting in clone AS-50S/P with reduced susceptibility
to SDX. AS-sens was also used to generate the current reference genome for P.
chabaudi. The reference genome is termed AS-WTSI; dotted lines represent possible
divergence due to passage history. Veriﬁed mutations are indicated. Dihydrofolate
reductase (dhfr), chromosome (chr), multi-drug resistance protein 2 gene (mdr2).ing SDX treatment was associated with inheritance of AS alleles,
whilst for PYR and S/P, growth was associated with inheritance
of AJ alleles.
Those data suggested that a mutation on chr13 in AS-50S/P rel-
ative to AS-PYR increased the SDX resistance (of a PYR-resistant
parasite). Here, we have re-sequenced the whole genome of the
SDX-resistant clone of P. chabaudi (AS-50S/P) using Solexa
paired-end short reads to identify point mutations, small indels
(63 bp) and, for key genes, copy number variations (CNVs) too.2. Materials and methods
2.1. Parasite lines, maintenance, parasite preparation and DNA
extraction
Plasmodium chabaudi clone AS-50S/P of the AS-lineage (Hayton
et al., 2002; Fig. 1) was routinely inoculated, passaged in CBA mice
(4–6 weeks) and cryopreserved as previously described (Walliker
et al., 1975). Parasites were prepared and DNA extracted as previ-
ously described (Grech et al., 2002), ensuring that host white cells
were removed by CF11 cellulose (Whatman, UK) and Plasmodipur
ﬁlters (Eurodiagnostica, The Netherlands).2.2. Illumina Solexa genome re-sequence analysis
Clone AS-sens was previously re-sequenced using the Illumina
(Solexa) platform with 36 bp single reads (Hunt et al., 2010), while
clone AS-50S/P was sequenced for this study using 50 bp paired-
end reads, at a mean genome coverage of approximately 45 reads
per nucleotide. Individual sequence strings (reads) from each clone
were aligned against an isogenic AS reference sequence (AS-WTSI
(Fig. 1), provided by the Pathogen Sequencing Group, Wellcome
Trust Sanger Institute, UK) using two different software packages;
MAQ (Mapping and Assembly with Quality; Li et al., 2008) and SSA-
HA2 (Sequence Search and Alignment by Hashing Algorithm; Ning
et al., 2001). A permissive insert size range (40–500 bp) was chosen
for the alignment of paired-end reads. The AS-WTSI sequence data
consisted of a recently completed assembly and annotation made
available during this investigation (ftp://ftp.sanger.ac.uk/pub/
pathogens/P_chabaudi/September_2009_assembly/). The detection
of single nucleotide polymorphisms (SNPs) was performed using
MAQ and SSAHA2, as described previously, with a minimum cover-
age of three reads chosen to call a potential SNP prior to further
quality analysis (Hunt et al., 2010). Lists obtained for AS-sens and
AS-50S/P were compared in order to remove candidate SNPs which
did not arise within the lineage. All putative point mutations pro-
posed by MAQ and/or SSAHA2 were veriﬁed by di-deoxy
sequencing.
Small indels (63 bp) were predicted using the internal algo-
rithm of SSAHA2. The potential indel list was ﬁltered against a list
previously obtained for clone AS-sens (Hunt et al., 2010), in order
to remove calls not unique to AS-50S/P. A limited number of the
small indel calls were investigated by di-deoxy sequencing.
No genome-wide large indel or CNV prediction was attempted
using SSAHA2 because no appropriately sequenced (i.e., using
paired-end reads) AS-sens genome was available to act as a ‘‘ﬁlter”
(Hunt et al., 2010) to remove the large number of candidates which
are not exclusive to the mutant clone.
However, a list of potential indels (including indels >3 bp) was
produced using the internal MAQ prediction algorithm. This algo-
rithm is only available for genomes sequenced using paired-end
reads. Again, no appropriate ‘‘ﬁlter” could be used to remove those
indels not unique to AS-50S/P. However, the list of small indels ob-
tained with MAQ was compared with the small indel predictions of
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were retained as candidates.
To detect gene ampliﬁcations, the fold-coverage of sequence
reads mapping to individual genes was measured using Artemis
(Rutherford et al., 2000) and the coverage plot obtained from
SSAHA2 (see Hunt et al., 2010). The gene-speciﬁc average fold-
coverage was divided by the mean genome coverage to produce
a ‘‘relative coverage” in AS-sens and AS-50S/P. A ‘‘comparative
coverage” index was produced by dividing the relative coverage
of the mutant clone by that of AS-sens. If the ‘‘comparative cover-
age” index was >1.5 it was taken as evidence of gene ampliﬁcation.
A known gene duplication in the multi-drug resistance gene 1
(mdr1, PCHAS_123820) in a clone previously selected for meﬂo-
quine resistance (AS-15MF; Cravo et al., 2003) and which has also
been Solexa sequenced (unpublished data) was used as a positive
control.2.3. Protein function prediction
Information on predicted proteins was extracted from the Plas-
moDB database (http://www.plasmodb.org/) for all mutations con-
ﬁrmed by di-deoxy sequencing. In the case of hypothetical proteins,
the amino acid sequences were submitted to Pfam (http://
www.pfam.sanger.ac.uk) and Prosite (http://www.expasy.ch/pro-
site/) for the identiﬁcation of protein domains, functional sites
and protein families. HMMTOP (http://www.enzim.hu/hmmtop/)
was used for the prediction of transmembrane domains.3. Results
3.1. Genome re-sequencing
The genome of clone AS-50S/P was sequenced as 50 bp paired-
end reads using the Illumina short read sequencing platformTable 1
Summary table of all mutations (single nucleotide polymorphisms (SNPs) and indels) identi
Quality (MAQ) and Sequence Search and Alignment by Hashing Algorithm (SSAHA2) so
conﬁrmed mutations, ‘‘high” indicates non-conﬁrmed high conﬁdence putative mutation
mutations, while ‘‘NO” indicates false positives rejected after di-deoxy sequencing. Only con
indels and copy number variations (CNVs), whereas low conﬁdence (expected to be negated
on SSAHA2.
Chr’some Type Analysis Start
(indels
only)
End Reference
base
Base in
AS-50SP
Base
inde
qual
Putative SNPs
2 SNP MAQ/SSAHA 200,295 T C 99
7 SNP MAQ/SSAHA 994,546 G A 99
13 SNP MAQ/SSAHA 613,601 T G 47
14 SNP SSAHA 711,800 T G 37
14 SNP MAQ/SSAHA 936,945 T G 40
14 SNP SSAHA 951,458 T A 10
bin SNP SSAHA 107,354 A C 25
bin SNP SSAHA 411,999 T C 14
Putative indels Size
2 Insert SSAHA 378,527 378,527 1 8/12
3 Insert SSAHA 409,429 409,429 1 6/10
7 Deletion SSAHA 779,270 779,270 1 120/
7 Deletion SSAHA 876,894 876,927 34
8 Insert SSAHA 854,448 854,448 1 2/4
9 Insert SSAHA 60,998 60,998 1 10/1
9 Deletion SSAHA 1113,660 1113,660 1 23/2
10 Deletion SSAHA/MAQ 290,663 290,663 1 26/3
11 Insert SSAHA 694,180 694,180 1 98/1
13 Insert SSAHA 1703,059 1703,059 1 48/3
bin Deletion SSAHA 262,255 262,255 1 20/1
aa, Amino acid.(Solexa). These reads were mapped against the reference genome
(assembly of September 2009, see Section 2.2) using two software
packages: MAQ (Li et al., 2008) and SSAHA2 (Ning et al., 2001). In
total, 19,132,804 short paired-end reads were produced. Ninety
percent of those reads mapped to the genome in MAQ and 92%
in SSAHA2. Of those, 17,943,606 (i.e., approximately 90% of the to-
tal reads) mapped uniquely to the reference genome in SSAHA2.
The average length of the paired-end read intervals was 207 bp
with the frequency distribution shown in Supplementary Fig. S2.
Eighty-nine percent of the nucleotides in the genome were covered
by at least 10 reads in SSAHA2. The scaffolded assembly yielded an
average genome-wide read coverage of 47.0 or 44.4 reads per
nucleotide (MAQ and SSAHA2, respectively).
3.2. SNP detection
Both MAQ and SSAHA2 were used to call SNPs. SNP calls were
ﬁltered against an equivalent list of SNPs identiﬁed by Solexa re-
sequencing of the susceptible progenitor clone AS-sens (Hunt
et al., 2010) in order to produce a list of predicted mutations aris-
ing in the lineage between AS-sens and AS-50S/P. Four point muta-
tions were identiﬁed by both MAQ and SSAHA2. They appear on
chr02, chr07, chr13 and chr14 (Table 1). They include non-synon-
ymous substitutions in dhfr (chr07, S106N PCHAS_072830, SSAHA
quality score 99), in a gene encoding an ABC transporter, multi-
drug resistance protein 2 (MDR2), (chr13, K392Q PCHAS_131500,
quality score 47), in a gene encoding a small conserved protein
(chr02, E109G PCHAS_020660, quality score 99), and an intergenic
mutation (T936,945G) lying between two genes coding for two
conserved Plasmodium proteins (chr14, PCHAS_142590 and
PCHAS_142600, quality score 40). The gene identiﬁcations (IDs)
and their presumed orthologues in P. falciparum are given in Ta-
ble 1. Those four mutations were conﬁrmed by ampliﬁcation and
di-deoxy sequencing, and their origin within the AS lineage deter-
mined by sequencing AS-sens, AS-PYR1 and AS-50S/P (Fig. 1).ﬁed in the Plasmodium chabaudi clone AS-50S/P using the Mapping and Assembly with
ftwares. The status of each mutation is highlighted in bold letters. ‘‘YES” indicates
s (based on quality scores), ‘‘low” indicates non-conﬁrmed low conﬁdence putative
ﬁrmed (‘‘YES”), rejected (‘‘NO”) and high conﬁdence (‘‘high”) mutations are shown for
) SNPs (‘‘low”) are also shown. Base quality scores and indel quality scores were based
/
l
ity
Conﬁrmation
of mutation
by di-deoxy
sequencing
P. chabaudi
gene ID
aa
change
P. chabaudi
nearest
gene ID
Plasmodium
falciparum
orthologue
YES PCHAS_020660 E109G PFA0250w
YES PCHAS_072830 S106 N PFD0830w
YES PCHAS_131500 K392Q PF14_0455
NO 5-PCHAS_141940 PF13_0106
YES 5-PCHAS_142600 PF08_0081
NO 5-PCHAS_142640 PF08_0083
low PCHAS_000260 None
low PCHAS_001050-3 None
high PCHAS_021100 MAL7P1.154a
high PCHAS_031150 PFB0560w
46 high PCHAS_072120 MAL8P1.65
YES PCHAS_072420-3 PF08_0067
NO PCHAS_082240 PFI1065c
1 high PCHAS_090150-5 PF11_0052
4 high PCHAS_093250 PF11_0361
1 NO 3-PCHAS_100680 PFD0460c
42 high 3-PCHAS_111970 PFF1025c
3 high PCHAS_134540-5 MAL13P1.139a
8 high 5-PCHAS_000700 None
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Lew, 1990; Cheng and Saul, 1994) and arises, as expected, in AS-
PYR1 during PYR selection. The intergenic point mutation on
chr14 (T936,945G) was conﬁrmed by dideoxy sequencing as
appearing ﬁrst in AS-PYR1. Consultation of the PlasmoDB and Plas-
moPredict databases, as well as a search for matches on the Pfam
and Prosite search engines, did not yield any signiﬁcant hits point-
ing to a potential function for the two proteins ﬂanking this
mutation.
The point mutation on chr02 on the other hand was conﬁrmed
as arising in AS-50S/P during selection by S/P. No functional predic-
tions were made for the mutated gene (PCHAS_020660) and the
E109G mutation could not be placed within any recognised protein
domain.
On chr13, MDR2 K392Q also arises in AS-50S/P during selection
by S/P. The mutation is located within the ﬁfth of 10 predicted
transmembrane domains of this putative ABC transporter (ABCB3;
Sauvage et al., 2009) protein. It substitutes a neutral polar gluta-
mine for a positively charged lysine. Importantly, previous QTL
analysis of the AS-50S/P  AJ genetic cross showed that genetic
markers mapping to chr13 were linked to SDX resistance (Hayton
et al., 2002). Speciﬁcally, on chr13, mdr2 maps between those
markers most closely linked to SDX resistance: it lies approxi-
mately 100 kb downstream of marker aldoI (currently annotated
as fructose-bisphosphate aldolase, PCHAS_131180, located approx-
imately at position 510,000) and 200 kb upstream to marker g6pdh
(glucose-6-phosphate dehydrogenase, PCHAS_132080, located
approximately at position 829,000) (Supplementary Fig. S3). In or-
der to estimate the likelihood that a potential point mutation in the
proximity may have been missed due to insufﬁcient read coverage,
a region spanning 400 kb upstream and downstream of the mdr2
gene was selected and the proportion of nucleotides within this
area that were covered by less than three reads (i.e., the minimum
for calling a SNP in both SSAHA2 and MAQ) was estimated as 0.4%.
Across the whole of chr13, this proportion rose to 1.4%. Both values
indicate a very low likelihood of any SNP having been missed on
chr13 due to insufﬁcient coverage, and strongly suggest that the
mutation on mdr2 is the sole mutation linked with the SDX-
resistant phenotype.
Four additional low quality SNP calls were made by SSAHA2
only (Table 1). Excluding a putative point mutation on chr14
(T711,800G, coverage 11, quality score 37), the remaining calls
were both of lower quality and lower coverage than the SNPs iden-
tiﬁed by both MAQ and SSAHA2. One call on chr14 (T951,458A)Table 2
Gene copy number by Solexa sequencing fold-coverage analysis. Comparative coverage (bol
and multi-drug resistance protein 1 (mdr1) in the Plasmodium chabaudi mutant clone AS-5
gene copy number as shown for the mdr1 gene in mutant clone AS-15MF. mdr1, multi-
dihydropteroate synthase; dhfs, dihydrofolate synthase; 6-pthps, 6-pyruvoyltetrahydropter
Mutant clone Gene Mean coveragea
AS-sens Mutant clone
AS-50S/P Genomed 39.48 44.44
mdr1 53.39 74.59
gtpch 45.31 34.77
dhfr 46.01 45.48
dhps 45.03 45.78
dhfs 48.71 49.76
6-pthps 55.96 54.28
shmt 52.43 66.62
AS-15MF Genomed 39.48 53.96
mdr1 52.39 150.02
a Mean coverage is the mean number of reads for all bases within the coding region
b Relative coverage equals mean coverage of the gene divided by mean coverage for t
c Comparative coverage is the relative coverage of the mutant clone gene divided by
d Mean read coverage across the whole genome, excluding unassigned contigs.had a quality score of 10 and a read depth of 3. Both of these
chr14 calls were negated by PCR and di-deoxysequencing, and
therefore deemed as false-positives. The remaining two calls,
namely A107,354C (read coverage of 5 and quality score of 25)
and T411,999C (read coverage of 4 and quality score of 14) mapped
to a composite ‘‘chromosome” of contigs not yet located to any
chromosome (‘‘bin”) and lay within or near to genes coding for
members of the chabaudi Interspersed Repeat (cir) family. These
two point mutations could not be veriﬁed by di-deoxy sequencing
because relevant DNA fragments could not be ampliﬁed. No SNP
calls were uniquely proposed by MAQ.
3.3. Indel detection
SSAHA2 was used to identify small indels (63 bp), which were
further conﬁrmed by MAQ analysis. Potential large indels (>3 bp)
were only predicted through MAQ, due to the lack of an appropri-
ately re-sequenced (i.e., with paired-end reads) susceptible parent
AS-sens to act as a ﬁlter for the SSAHA2-based analysis (see Hunt
et al., 2010). A total of 62 indels were predicted (see Supplemen-
tary Table S1). Fifty-eight were classiﬁed as small indels, while four
were classiﬁed as large indels. Table 1 shows the 11 indels that
were either conﬁrmed (green), rejected (red) by di-deoxy sequenc-
ing or those that were considered as being high conﬁdence muta-
tions (yellow), based on read coverage and SSAHA2 quality scores
as described previously (Hunt et al., 2010). All large indels, with
one exception (see below in this section) were classiﬁed as low
conﬁdence mutations, due to the lack of appropriate ﬁltering in
the MAQ analysis (see Section 2.2).
Only two indels (a 1 bp deletion at position 290,663 on chr10
and a 1 bp insertion at position 2,070,154 on chr14) were identi-
ﬁed by SSAHA2 and MAQ (Table 1 and Supplementary Table S1).
Di-deoxy sequencing of the deletion on chr10 indicated that this
call was a false positive. Of the remaining indels, only one was ana-
lysed by di-deoxy sequencing (a single nucleotide insertion at po-
sition 854,448 on chr08) and rejected as a false positive (Table 1).
No further re-sequencing was undertaken, but due to the large
number of indels compared with point mutations and previous
experience with a similar data set (Hunt et al., 2010) it is predicted
that the vast majority of these calls will be false positives.
One indel that was not predicted by the MAQ algorithm was
veriﬁed in the course of this study. Its presence was predicted
based on previous whole-genome re-sequencing analysis (and val-
idation) of related clones of the same lineage, using a comparatived) gives an estimate of gene copy number for genes of the folate biosynthetic pathway
0S/P and wild-type clone AS-sens. Comparative coverage gives a reliable estimate of
drug resistance 1; gtpch, GTP cyclohydrolase I; dhfr, dihydrofolate reductase; dhps,
in synthase; shmt, serine hydroxymethyltransferase.
Relative coverageb Comparative coverage
in mutant clonec
AS-sens Mutant clone
1.00 1.00 1.00
1.35 1.68 1.24
1.15 0.78 0.68
1.17 1.02 0.88
1.14 1.03 0.90
1.23 1.12 0.91
1.42 1.22 0.86
1.33 1.50 1.13
1.00 1.00 1.00
1.33 2.78 2.10
of the genome or gene.
he whole genome.
the relative coverage of wild-type AS-sens gene. See Section 2 for details.
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2010); an approach which could not be applied here due to the lack
of a paired-end sequenced AS-sens genome for comparison. The
34 bp deletion (located between positions 876,894 and 876,927
on chr7) was veriﬁed by di-deoxy sequencing (Table 1). This dele-
tion falls immediately downstream (and 30) of a gene encoding a
conserved Plasmodium protein (PCHAS_072420, homologous to
PF08_0067 in P. falciparum), which contains four transmembrane
domains, a signal peptide and a ubiquitin-like fragment. It is also
located upstream (and 50) of a putative eukaryotic translation fac-
tor (PCHAS_072430, homologous to MAL8P1.83 in P. falciparum).3.4. CNV detection
Gene copy number variation in dhfr and GTP cyclohydrolase
have been identiﬁed (Cowman and Lew, 1990; Kidgell et al.,
2006) and may modulate responses to antifolate drugs. We inves-
tigated the copy numbers of genes encoding enzymes of the folate
biosynthetic pathway (Supplementary Fig. S1) using a validated
analysis of the coverage of Solexa reads in these genes. Table 2
shows that the relative read-coverages for GTP cyclohydrolase I,
6-pyruvoyltetrahydropterin synthase, dhps, dihydrofolate syn-
thase, dhfr and serine hydroxymethyltransferase were no different
in AS-50S/P compared with AS-sens. In contrast, the relative read
coverage for mdr1 in AS-15MF (Cravo et al., 2003) was twice that
in AS-sens, reﬂecting the previously known duplication in that
clone.4. Discussion
Of the four point mutations identiﬁed, two, namely S106N dhfr
(chr07) and the intergenic point mutation on chr14 were already
present in the PYR-resistant progenitor clone, AS-PYR1.
Two point mutations occurred between AS-PYR and the S/P-
resistant clone, AS-50S/P. These are located on chr02 and chr13.
There were no further mutations in dhps or other known folate
genes which might account for the increased resistance to SDX in
AS-50S/P. These data support a previous study which identiﬁes a
small number of point mutations accumulating during the evolu-
tion of other complex drug resistance phenotypes (Hunt et al.,
2010) and conﬁrms how this model and technology are well suited
for complete genome re-sequencing of isogenic strains of P. chab-
audi and identiﬁcation of critical mutations conferring drug-
resistance phenotypes.
Of these three mutations, that located on chr13 is most signiﬁ-
cant to SDX responses because two genetic markers most linked to
SDX responses in QTL analysis mapped to chr13 (Hayton et al.,
2002). These markers (numbers 19 and 37; Hayton et al., 2002)
map to g6pdh (PCHAS_132080) and fructose-bisphosphate aldolase
(PCHAS_131180), respectively (Carlton et al., 1998). The K392Q
MDR2 mutation maps between these two markers (Supplementary
Fig. S3), 216 kb upstream of the former and 104 kb downstream
of the latter. Because no other mutations were indicated on this
chromosome, we propose that the mutant AS mdr2 allele contrib-
utes to increased resistance to SDX.
In P. falciparum, increased resistance to SDX in PYR-resistant par-
asites often involves mutations in dhps, but other mechanisms may
exist. For example, SDX-resistant P. falciparum isolates with wild-
type dhps sequences have been characterised (Mberu et al., 2000).
Furthermore, recent work by Dahlström et al. (2009) has suggested
that mutations (I876V and K1466R) in the multi-drug resistance
protein 1 (encoded by mrp1 (PFA0590w) may mediate an alterna-
tive mechanism modulating S/P resistance. For example, they pro-
pose that this mutation may result in higher concentrations of
exogenous folate beingmade available for the cell. Here, we identifymutations in MDR2, another ABC transporter (Klokouzas
et al., 2003; Rosenberg et al., 2006; Sauvage et al., 2009), which
may function similarly.
In P. falciparum, MDR2 (PF14_0455) is characterised as an ABCB
(pfABCB3) transporter (Sauvage et al., 2009) belonging to the same
subfamily as MDR1 (PFE1150w, pfABCB1) but distinct from the
MRP1 transporter (PFA0590w, PfABCC1) investigated by
Dahlström et al. (2009), which belongs to the ABCC subfamily of
ABC transporters. MDR2 is located both in the plasma membrane
of the parasite as well as in the food vacuole membrane and con-
tains 10 transmembrane domains and a single nucleotide binding
site (Zalis et al., 1993; Rubio and Cowman, 1994). It is related to
the MDR1 ABC transporter implicated in resistance to multiple
anti-malarial drugs, notably meﬂoquine (Duraisingh and Cowman,
2005). MDR2 is associated with heavy metal ion efﬂux and resis-
tance to cadmium (Rosenberg et al., 2006) but evidence of its
involvement in responses to anti-malarial drugs is weak or con-
ﬂicting (Ekong et al., 1993; Rubio and Cowman, 1994; Wurtz
et al., 2010). MDR2 may be involved in the transport of organic an-
ions, such as folate or pABA, as suggested for MRP1 (Dahlström
et al., 2009), and due to the structural similarity between pABA
and sulphadoxine, the transport of SDX too. Independently of the
actual mechanism by which MDR2 mediates SDX resistance, its
role in SDX-resistant P. falciparum strains with wild-type dhps se-
quences (Mberu et al., 2000) may now be evaluated. The role of
mdr2 mutations in generating SDX resistance might also be exper-
imentally investigated using transfection approaches in either P.
chabaudi or P. falciparum.
Previous Solexa analysis of other clones of the AS lineage of P.
chabaudi parasites identiﬁed a 34 bp deletion on chr07 located
120 kb upstream of dhfr (Hunt et al., 2010). This mutation is pres-
ent in AS-PYR1 but not AS-sens. Its relationship to PYR resistance
or to possible ﬁtness costs of a dhfr mutation is not known. It is lo-
cated 47 bp downstream of the 30 end of a gene (PCHAS_072420,
orthologous to PF08_0067) that encodes a conserved Plasmodium
spp. protein of unknown function. This protein is predicted to con-
tain four transmembrane domains and a signal peptide. Previous
genetic linkage data from a genetic cross between the P. falciparum
clones Dd2 and HB3 (with different dhfr and dhps alleles) and se-
quence analysis of other P. falciparum isolates suggest the possibil-
ity that the ‘folate effect’ was associated with a gene closely linked
to dhfr (Wang et al., 1997).
Despite the apparent simplicity of the drug/target interactions
in the folate pathway, the patterns of antifolate drug susceptibility
can be complex. We note that Metabolic Control Analysis
(Hornberg et al., 2007) provides a conceptual framework for under-
standing the distributed control of ﬂux within metabolic pathways
(in contrast to the construct ‘rate-limiting step’). In folate biosyn-
thesis, the control of pathway ﬂux may be shared between dhps
activity and dhfr activity (and other activities, such as folate trans-
porters or GTP cyclohydrolase activity; Kidgell et al., 2006; Nair
et al., 2008), and that this distribution may change as mutations
in dhps or dhfr accumulate and the kinetic parameters of the en-
zymes change. The synergistic action of SDX and PYR, the increased
susceptibility to SDX when dhfrmutations generate PYR resistance,
the ‘folate effect’ and the role of mutations in putative folate trans-
porters may be more clearly understood with such a theoretical
framework.
To summarise, our analysis revealed severalmutations in a clone
of P. chabaudi selected for resistance by SDX–PYR drug treatment. In
particular, a non-synonymous substitution on the gene encoding
MDR2 was identiﬁed and found to correlate with markers previ-
ously described as being associated with SDX resistance. It is pro-
posed that mdr2 may underlie the SDX resistance phenotype
either by directlymediating transport of the drug itself or indirectly
by mediating the transport of exogenous folate (or pABA)
170 A. Martinelli et al. / International Journal for Parasitology 41 (2011) 165–171which may counteract the activity of SDX (the so-called ‘folate
effect’).
Acknowledgments
A.M. and G.H. were supported by the Fundação para a Ciência e
a Tecnologia (FCT) of Portugal (Grant nos.: SFRH/BPD/35017/2007
and SFRH/BD/63129/2009, respectively). P.H. was funded by the
Wellcome Trust Centre-in-Development in Immunity, Infection
and Evolution (UK) (082611/Z/07/Z). Medical Research Council,
UK (G0400476) and FCT (project no. PTDC/SAU-MII/65028/2006)
supported the research. We thank Karen Hayton (National Insti-
tutes of Health, USA) for experimental details, and Thomas D. Otto
(Wellcome Trust Sanger Institute, UK) for assistance with use of
SSAHA2. Access to the P. chabaudi genome assembly was provided
by the Pathogen Sequencing Unit at the Wellcome Trust Sanger
Institute, UK and can be obtained from ftp://ftp.sanger.ac.uk/pub/
pathogens/P_chabaudi/September_2009_assembly/.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ijpara.2010.08.008.
References
Basco, L.K., Eldin de Pecoulas, P., Wilson, C.M., Le Bras, J., Mazabraud, A., 1995. Point
mutations in the dihydrofolate reductase-thymidylate synthase gene and
pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol.
Biochem. Parasitol. 69, 135–138.
Carlton, J.M., Mackinnon, M., Walliker, D., 1998. A chloroquine resistance locus in
the rodent malaria parasite Plasmodium chabaudi. Mol. Biochem. Parasitol. 93,
57–72.
Carlton, J.M., Hayton, K., Cravo, P.V., Walliker, D., 2001. Of mice and malaria
mutants: unravelling the genetics of drug resistance using rodent malaria
models. Trends Parasitol. 17, 236–242.
Cheng, Q., Saul, A., 1994. The dihydrofolate reductase domain of rodent malarias:
point mutations and pyrimethamine resistance. Mol. Biochem. Parasitol. 65,
361–363.
Cowman, A.F., Lew, A.M., 1990. Chromosomal rearrangements and point mutations
in the DHFR-TS gene of Plasmodium chabaudi under antifolate selection. Mol.
Biochem. Parasitol. 42, 21–29.
Cravo, P.V., Carlton, J.M., Hunt, P., Bisoni, L., Padua, R.A., Walliker, D., 2003. Genetics
of meﬂoquine resistance in the rodent malaria parasite Plasmodium chabaudi.
Antimicrob. Agents Chemother. 47, 709–718.
Culleton, R., Martinelli, A., Hunt, P., Carter, R., 2005. Linkage group selection: rapid
gene discovery in malaria parasites. Genome Res. 15, 92–97.
Dahlström, S., Veiga, M.I., Mårtensson, A., Björkman, A., Gil, J.P., 2009.
Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance
protein 1) amino acid 1466 associated with resistance to sulfadoxine–
pyrimethamine treatment. Antimicrob. Agents Chemother. 53, 2553–2556.
Duraisingh, M.T., Cowman, A.F., 2005. Contribution of the pfmdr1 gene to
antimalarial drug-resistance. Acta Trop. 94, 181–190.
Eastham, G.M., Rieckmann, K.H., 1983. The activity of pyrimethamine and
sulphadoxine against Plasmodium falciparum determined by the in vitro
microtechnique. Trans. R. Soc. Trop. Med. Hyg. 77, 91–93.
Ekong, R.M., Robson, K.J., Baker, D.A., Warhurst, D.C., 1993. Transcripts of the
multidrug resistance genes in chloroquine-sensitive and chloroquine-resistant
Plasmodium falciparum. Parasitology 106, 107–115.
Grech, K., Martinelli, A., Pathirana, S., Walliker, D., Hunt, P., Carter, R., 2002.
Numerous, robust genetic markers for Plasmodium chabaudi by the method of
ampliﬁed fragment length polymorphism. Mol. Biochem. Parasitol. 123, 95–
104.
Gregson, A., Plowe, C.V., 2005. Mechanisms of resistance of malaria parasites to
antifolates. Pharmacol. Rev. 57, 117–145.
Hayton, K., Ranford-Cartwright, L.C., Walliker, D., 2002. Sulfadoxine–
pyrimethamine resistance in the rodent malaria parasite Plasmodium
chabaudi. Antimicrob. Agents Chemother. 46, 2482–2489.
Hornberg, J.J., Bruggeman, F.J., Bakker, B.M., Westerhoff, H.V., 2007. Metabolic
control analysis to identify optimal drug targets. Prog. Drug Res. 64. 171, 173–
189.
Hunt, P., Martinelli, A., Borges, S., Modrzynska, K., Creasey, A., Rodrigues, L., Beraldi,
D., Loewe, L., Kumar, S., Thomson, M., Urmi, T., Otto, T., Pain, A., Blaxter, M.,
Cravo, P., 2010. Experimental evolution, genetic analysis and genome re-
sequencing reveals the mutation conferring artemisinin resistance in an
isogenic lineage of malaria parasites. BMC Genomics. 11, 499.
Hyde, J.E., 2005. Exploring the folate pathway in Plasmodium falciparum. Acta Trop.
94, 191–206.Jacobs, R.L., 1964. Role of p-aminobenzoic acid in Plasmodium berghei infection in
the mouse. Exp. Parasitol. 15, 213–225.
Kidgell, C., Volkman, S.K., Daily, J., Borevitz, J.O., Plouffe, D., Zhou, Y., Johnson, J.R., Le
Roch, K., Sarr, O., Ndir, O., Mboup, S., Batalov, S., Wirth, D.F., Winzeler, E.A., 2006.
A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog. 2,
e57.
Klokouzas, A., Shahi, S., Hladky, S.B., Barrand, M.A., van Veen, H.W., 2003. ABC
transporters and drug resistance in parasitic protozoa. Int. J. Antimicrob. Agents
22, 301–317.
Krungkrai, J., Webster, H.K., Yuthavong, Y., 1989. De novo and salvage biosynthesis
of pteroylpentaglutamates in the human malaria parasite, Plasmodium
falciparum. Mol. Biochem. Parasitol. 32, 25–37.
Li, H., Ruan, J., Durbin, R., 2008. Mapping short DNA sequencing reads and calling
variants using mapping quality scores. Genome Res. 18, 1851–1858.
Mberu, E.K., Mosobo, M.K., Nzila, A.M., Kokwaro, G.O., Sibley, C.H., Watkins, W.M.,
2000. The changing in vitro susceptibility pattern to pyrimethamine/
sulfadoxine in Plasmodium falciparum ﬁeld isolates from Kiliﬁ, Kenya. Am. J.
Trop. Med. Hyg. 62, 396–401.
McCollum, A.M., Basco, L.K., Tahar, R., Udhayakumar, V., Escalante, A.A., 2008.
Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and
pyrimethamine resistance alleles in a population from central Africa.
Antimicrob. Agents Chemother. 52, 4089–4097.
Milhous, W.K., Weatherly, N.F., Bowdre, J.H., Desjardins, R.E., 1985. In vitro activities
of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob.
Agents Chemother. 27, 525–530.
Nair, S., Williams, J.T., Brockman, A., Paiphun, L., Mayxay, M., Newton, P.N.,
Guthmann, J.P., Smithuis, F.M., Hien, T.T., White, N.J., Nosten, F., Anderson, T.J.,
2003. A selective sweep driven by pyrimethamine treatment in southeast asian
malaria parasites. Mol. Biol. Evol. 20, 1526–1536.
Nair, S., Millerm, B., Barends, M., Jaideem, A., Patel, J., Mayxay, M., Newton, P.,
Nosten, F., Ferdig, M.T., Anderson, T.J., 2008. Adaptive copy number evolution in
malaria parasites. PLoS Genet. 4, e1000243.
Nash, D., Nair, S., Mayxay, M., Newton, P.N., Guthmann, J.P., Nosten, F., Anderson,
T.J., 2005. Selection strength and hitchhiking around two anti-malarial
resistance genes. Proc. Biol. Sci. 272, 1153–1161.
Ning, Z., Cox, A.J., Mullikin, J.C., 2001. SSAHA: a fast search method for large DNA
databases. Genome Res. 11, 1725–1729.
Nosten, F., White, N.J., 2007. Artemisinin-based combination treatment of
falciparum malaria. Am. J. Trop. Med. Hyg. 77, 181–192.
Nzila, A., 2006. The past, present and future of antifolates in the treatment of
Plasmodium falciparum infection. J. Antimicrob. Chemother. 57, 1043–1054.
Nzila-Mounda, A., Mberu, E.K., Sibley, C.H., Plowe, C.V., Winstanley, P.A., Watkins,
W.M., 1998. Kenyan Plasmodium falciparum ﬁeld isolates: correlation between
pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the
dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42, 164–
169.
Peterson, D.S., Walliker, D., Wellems, T.E., 1988. Evidence that a point mutation in
dihydrofolate reductase-thymidylate synthase confers resistance to
pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA 85, 9114–
9118.
Plowe, C.V., Cortese, J.F., Djimde, A., Nwanyanwu, O.C., Watkins, W.M., Winstanley,
P.A., Estrada-Franco, J.G., Mollinedo, R.E., Avila, J.C., Cespedes, J.L., Carter, D.,
Doumbo, O.K., 1997. Mutations in Plasmodium falciparum dihydrofolate
reductase and dihydropteroate synthase and epidemiologic patterns of
pyrimethamine–sulfadoxine use and resistance. J. Infect. Dis. 176, 1590–1596.
Rosenberg, E., Litus, I., Schwarzfuchs, N., Sinay, R., Schlesinger, P., Golenser, J.,
Baumeister, S., Lingelbach, K., Pollack, Y., 2006. pfmdr2 confers heavy metal
resistance to Plasmodium falciparum. J. Biol. Chem. 281, 27039–27045.
Rubio, J.P., Cowman, A.F., 1994. Plasmodium falciparum: the pfmdr2 protein is not
overexpressed in chloroquine-resistant isolates of the malaria parasite. Exp.
Parasitol. 79, 137–147.
Rutherford, K., Parkhill, J., Crook, J., Horsnell, T., Rice, P., Rajandream, M.A., Barrell, B.,
2000. Artemis: sequence visualization andannotation. Bioinformatics 16, 944–945.
Sauvage, V., Aubert, D., Escotte-Binet, S., Villena, I., 2009. The role of ATP-binding
cassette (ABC) proteins in protozoan parasites. Mol. Biochem. Parasitol. 167,
81–94.
Sirawaraporn, W., Sathitkul, T., Sirawaraporn, R., Yuthavong, Y., Santi, D.V., 1997.
Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase.
Proc. Natl. Acad. Sci. USA 94, 1124–1129.
Triglia, T., Cowman, A.F., 1994. Primary structure and expression of the
dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad.
Sci. USA 91, 7149–7153.
Triglia, T., Menting, J.G., Wilson, C., Cowman, A.F., 1997. Mutations in
dihydropteroate synthase are responsible for sulfone and sulfonamide
resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94, 13944–
13949.
Triglia, T., Wang, P., Sims, P.F., Hyde, J.E., Cowman, A.F., 1998. Allelic exchange at the
endogenous genomic locus in Plasmodium falciparum proves the role of
dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 17, 3807–
3815.
Walliker, D., Carter, R., Sanderson, A., 1975. Genetic studies on Plasmodium
chabaudi: recombination between enzyme markers. Parasitology 70, 19–24.
Wang, P., Read, M., Sims, P.F., Hyde, J.E., 1997. Sulfadoxine resistance in the human
malaria parasite Plasmodium falciparum is determined by mutations in
dihydropteroate synthetase and an additional factor associated with folate
utilization. Mol. Microbiol. 23, 979–986.
A. Martinelli et al. / International Journal for Parasitology 41 (2011) 165–171 171Wang, P., Brobey, R.K., Horii, T., Sims, P.F., Hyde, J.E., 1999. Utilization of exogenous
folate in the human malaria parasite Plasmodium falciparum and its critical role
in antifolate drug synergy. Mol. Microbiol. 32, 1254–1262.
Wu, Y., Kirkman, L.A., Wellems, T.E., 1996. Transformation of Plasmodium falciparum
malaria parasites by homologous integration of plasmids that confer resistance
to pyrimethamine. Proc. Natl. Acad. Sci. USA 93, 1130–1134.Wurtz, N., Briolant, S., Gil, M., Parquet, V., Henry, M., Baret, E., Amalvict, R., Almeras,
L., Rogier, C., Pradines, B., 2010. Synergy of meﬂoquine activity with
atorvastatin, but not chloroquine and monodesethylamodiaquine, and
association with the pfmdr1 gene. J. Antimicrob. Chemother. 65, 1387–1394.
Zalis, M.G., Wilson, C.M., Zhang, Y., Wirth, D.F., 1993. Characterization of the pfmdr2
gene for Plasmodium falciparum. Mol. Biochem. Parasitol. 62, 83–92.
